{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:39:54Z","timestamp":1792363194792,"version":"4.4.0"},"reference-count":20,"publisher":"CSIRO Publishing","issue":"4","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,12,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To share lessons learnt from the Sydney Local Health District (SLHD) rollout of respiratory syncytial virus (RSV) prevention products, and present data on immunisation uptake for mothers and babies in two maternity hospitals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Type of service<\/jats:title>\n                    <jats:p>Rollout of the RSV maternal vaccine and the injectable, long-acting monoclonal antibody nirsevimab for newborn infants to protect them from RSV infection and hospitalisation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Deidentified summary data from the electronic medical record on RSV immunisation status in two SLHD maternity hospitals were analysed descriptively as counts and proportions. The Consolidated Framework for Implementation Research was used as a lens to reflect on the rollout process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>RSV vaccination coverage in women giving birth in two SLHD hospitals improved from 4% in the first month of rollout (February 2025) to a range of 70\u201374% from June to September 2025. As antenatal coverage improved, the number of live born babies requiring nirsevimab decreased. Among eligible newborns, 36% of families declined nirsevimab, with reason for refusal not recorded. Documentation of RSV immunisation status improved as the rollout progressed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons learnt<\/jats:title>\n                    <jats:p>Engaging multidisciplinary leaders and clinicians is critical for a coordinated response and program rollout success. Leveraging existing education structures, staff meetings and using online prerecording can optimise clinician education. New programs take time to embed into routine clinical practice, and programs that involve delivering multiple immunisation products for distinct groups require clear messaging and systemic safeguards to prevent errors. Integrating immunisation into medical record workflows as standard practice can support program adoption and uptake.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/pu26011","type":"journal-article","created":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:57:06Z","timestamp":1792360626000},"source":"Crossref","is-referenced-by-count":0,"title":["Under pressure: lessons learnt from rapid implementation of the respiratory syncytial virus maternal vaccine and infant nirsevimab in Sydney, Australia"],"prefix":"10.1071","volume":"36","author":[{"given":"Isabella","family":"Townshend","sequence":"first","affiliation":[{"name":"Public Health Unit A , , , , .","place":["Camperdown, NSW, Australia"]},{"name":"Sydney Local Health District A , , , , .","place":["Camperdown, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7544-2876","authenticated-orcid":true,"given":"Kate","family":"Griew","sequence":"additional","affiliation":[{"name":"Maternity B , , , , .","place":["Camperdown, NSW, Australia"]},{"name":"Sydney Local Health District B , , , , .","place":["Camperdown, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Burke","sequence":"additional","affiliation":[{"name":"Pharmacy C , , , , .","place":["Camperdown, NSW, Australia"]},{"name":"Sydney Local Health District C , , , , .","place":["Camperdown, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3385-645X","authenticated-orcid":true,"given":"Vendula","family":"Blaya-Novakova","sequence":"additional","affiliation":[{"name":"Formerly of: Public Health Unit, Sydney Local Health District D , , , .","place":["Sydney, NSW, Australia"]},{"name":"Aboriginal Health & Medical Research Council of NSW E , , , .","place":["Sydney, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"Dashwood","sequence":"additional","affiliation":[{"name":"Maternity B , , , , .","place":["Camperdown, NSW, Australia"]},{"name":"Sydney Local Health District B , , , , .","place":["Camperdown, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Everett","sequence":"additional","affiliation":[{"name":"Maternity Informatics, Sydney Local Health District F , , , .","place":["Sydney, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Gupta","sequence":"additional","affiliation":[{"name":"Public Health Unit A , , , , .","place":["Camperdown, NSW, Australia"]},{"name":"Sydney Local Health District A , , , , .","place":["Camperdown, NSW, Australia"]},{"name":"School of Public Health G , , , , .","place":["Sydney, NSW, Australia"]},{"name":"The University of Sydney G , , , , .","place":["Sydney, NSW, Australia"]},{"name":"School of Medicine H , , , , .","place":["Sydney, NSW, Australia"]},{"name":"The University of Notre Dame H , , , , .","place":["Sydney, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"67","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"issue":"1","key":"2026101817570116800_R1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-17474-x","article-title":"Respiratory syncytial virus disease morbidity in Australian infants aged 0 to 6 months: a systematic review with narrative synthesis.","volume":"23","author":"Self","year":"2023","journal-title":"BMC Public Health"},{"issue":"4","key":"2026101817570116800_R2","doi-asserted-by":"publisher","first-page":"2079322","DOI":"10.1080\/21645515.2022.2079322","article-title":"RSV disease in infants and young children: Can we see a brighter future?","volume":"18","author":"Baraldi","year":"2022","journal-title":"Hum Vaccines Immunother"},{"key":"2026101817570116800_R3"},{"issue":"11","key":"2026101817570116800_R4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.5694\/mja2.52671","article-title":"Respiratory syncytial virus preventives for children in Australia: current landscape and future directions.","volume":"222","author":"Barnett","year":"2025","journal-title":"Med J Aust"},{"issue":"16","key":"2026101817570116800_R5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F Vaccine in pregnancy to prevent RSV illness in infants.","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"2026101817570116800_R6","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S1473-3099(25)00231-2","article-title":"Maternal vaccination to prevent severe RSV disease in infants.","volume":"25","author":"Zar","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"2026101817570116800_R7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants.","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"2026101817570116800_R8","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.71249","article-title":"Nirsevimab and acute bronchiolitis admissions in infants under one year of age.","volume":"60","author":"Andina Mart\u00ednez","year":"2025","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"2026101817570116800_R9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106466","article-title":"Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024.","volume":"90","author":"Wadia","year":"2025","journal-title":"J Infect"},{"issue":"11","key":"2026101817570116800_R10","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/S1473-3099(25)00233-6","article-title":"Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study.","volume":"25","author":"Torres","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026101817570116800_R11"},{"issue":"1","key":"2026101817570116800_R12","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2331872","article-title":"Positioning implementation science in national immunization programmes to improve coverage equity and advance progress toward Immunization Agenda 2030: An urgent global health imperative.","volume":"20","author":"Adamu","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"2026101817570116800_R13"},{"issue":"1","key":"2026101817570116800_R14","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-022-01245-0","article-title":"The updated consolidated framework for implementation research based on user feedback.","volume":"17","author":"Damschroder","year":"2022","journal-title":"Implement Sci"},{"issue":"1","key":"2026101817570116800_R15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-4-50","article-title":"Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science.","volume":"4","author":"Damschroder","year":"2009","journal-title":"Implementation Sci"},{"key":"2026101817570116800_R16","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2025.49.023","article-title":"Annual immunisation coverage report 2022.","volume":"49","author":"Hull","year":"2025","journal-title":"Commun Dis Intell (2018)"},{"key":"2026101817570116800_R17"},{"key":"2026101817570116800_R18"},{"key":"2026101817570116800_R19"},{"issue":"Supplement_1","key":"2026101817570116800_R20","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.828","article-title":"RSV prophylaxis with nirsevimab in infants: systematic review of early real-world evidence on effectiveness and impact.","volume":"12","author":"Wick","year":"2025","journal-title":"Open Forum Infect Dis"}],"container-title":["Public Health Research &amp; Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/pu\/article-pdf\/doi\/10.1071\/PU26011\/1973670\/pu26011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/pu\/article-pdf\/doi\/10.1071\/PU26011\/1973670\/pu26011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:57:07Z","timestamp":1792360627000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/pu\/article\/36\/4\/PU26011\/275752\/Under-pressure-lessons-learnt-from-rapid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12,10]]}},"URL":"https:\/\/doi.org\/10.1071\/pu26011","relation":{},"ISSN":["2204-2091"],"issn-type":[{"value":"2204-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"article-number":"PU26011"}}